Infliximab · people with chronic plaque psoriasis
Any systemic treatment probably leads to higher infliximab compared with placebo (moderate certainty).
2 findings from 1 review
Tildrakizumab · people with chronic plaque psoriasis
Any systemic treatment leads to higher tildrakizumab compared with placebo (high certainty).
2 findings from 1 review
Oral Tyrosine kinase 2 (TYK2) inhibitor · people with chronic plaque psoriasis
Any systemic treatment may leads to higher oral tyrosine kinase 2 (TYK2) inhibitor compared with placebo (low certainty).
2 findings from 1 review
Certolizumab · people with chronic plaque psoriasis
Any systemic treatment probably leads to higher certolizumab compared with placebo (moderate certainty).
2 findings from 1 review
Ciclosporin · people with chronic plaque psoriasis
It is very uncertain whether any systemic treatment changes ciclosporin compared with placebo (very low certainty).
2 findings from 1 review
Etanercept · people with chronic plaque psoriasis
Any systemic treatment probably leads to higher etanercept compared with placebo (moderate certainty).
2 findings from 1 review
Methotrexate · people with chronic plaque psoriasis
Any systemic treatment may leads to higher methotrexate compared with placebo (low certainty).
2 findings from 1 review
Tofacitinib · people with chronic plaque psoriasis
Any systemic treatment may leads to higher tofacitinib compared with placebo (low certainty).
2 findings from 1 review
Apremilast · people with chronic plaque psoriasis
Any systemic treatment probably leads to higher apremilast compared with placebo (moderate certainty).
2 findings from 1 review
Fumaric acid · people with chronic plaque psoriasis
It is very uncertain whether any systemic treatment changes fumaric acid compared with placebo (very low certainty).
1 finding from 1 review
Acitretin · people with chronic plaque psoriasis
It is very uncertain whether any systemic treatment changes acitretin compared with placebo (very low certainty).
2 findings from 1 review
Ixekizumab · people with chronic plaque psoriasis
Any systemic treatment probably leads to higher ixekizumab compared with placebo (moderate certainty).
2 findings from 1 review
Bimekizumab · people with chronic plaque psoriasis
Any systemic treatment showed no clear difference in bimekizumab compared with placebo (low certainty).
2 findings from 1 review
Risankizumab · people with chronic plaque psoriasis
Any systemic treatment probably leads to lower risankizumab compared with placebo (moderate certainty).
2 findings from 1 review
Ustekinumab · people with chronic plaque psoriasis
Any systemic treatment showed no clear difference in ustekinumab compared with placebo (moderate certainty).
2 findings from 1 review
Fumaric acid esters · people with chronic plaque psoriasis
It is very uncertain whether any systemic treatment changes fumaric acid esters compared with placebo (very low certainty).
1 finding from 1 review
Guselkumab · people with chronic plaque psoriasis
Any systemic treatment showed no clear difference in guselkumab compared with placebo (moderate certainty).
2 findings from 1 review
Adalimumab · people with chronic plaque psoriasis
Any systemic treatment showed no clear difference in adalimumab compared with placebo (moderate certainty).
2 findings from 1 review
Brodalumab · people with chronic plaque psoriasis
Any systemic treatment showed no clear difference in brodalumab compared with placebo (moderate certainty).
2 findings from 1 review
Secukinumab · people with chronic plaque psoriasis
Any systemic treatment showed no clear difference in secukinumab compared with placebo (moderate certainty).
2 findings from 1 review